Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price was down 5.1% during trading on Friday . The company traded as low as $4.22 and last traded at $4.23. Approximately 2,313,449 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 13,570,314 shares. The stock had previously closed at $4.45.
Analysts Set New Price Targets
A number of equities analysts have commented on RXRX shares. Leerink Partners reduced their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday, February 28th. Needham & Company LLC reduced their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Morgan Stanley reduced their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $7.60.
Check Out Our Latest Analysis on RXRX
Recursion Pharmaceuticals Stock Down 5.6%
The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -2.75 and a beta of 0.99. The firm has a 50 day moving average price of $4.91 and a 200-day moving average price of $6.40.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. During the same period last year, the company earned ($0.39) EPS. The company's revenue was up 7.2% compared to the same quarter last year. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.
Institutional Investors Weigh In On Recursion Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in RXRX. Private Trust Co. NA acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at about $27,000. AlphaQuest LLC acquired a new position in Recursion Pharmaceuticals in the first quarter valued at about $36,000. GAMMA Investing LLC lifted its stake in Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after buying an additional 2,026 shares during the period. Farther Finance Advisors LLC lifted its stake in Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after buying an additional 1,353 shares during the period. Finally, NewEdge Advisors LLC lifted its stake in Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after buying an additional 2,387 shares during the period. Institutional investors own 89.06% of the company's stock.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
